Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma

被引:7
作者
Markus, Efrat [1 ,2 ]
Trestman, Svetlana [2 ,3 ]
Cohen, Yael [2 ,3 ]
Angel, Yoel [2 ,4 ]
Sofer, Yael [1 ,2 ]
Mittelman, Moshe [2 ,5 ]
Avivi, Irit [2 ,3 ]
Stern, Naftali [1 ,2 ]
Izkhakov, Elena [1 ,2 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Inst Endocrinol Metab & Hypertens, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Inst Hematol, Tel Aviv, Israel
[4] Tel Aviv Sourasky Med Ctr, Dept Internal Med C, Tel Aviv, Israel
[5] Tel Aviv Sourasky Med Ctr, Dept Internal Med A, Tel Aviv, Israel
基金
英国科研创新办公室;
关键词
Smoldering multiple myeloma; Hyperlipidemia; Metabolic changes; C-REACTIVE PROTEIN; ACUTE-PHASE PROTEINS; INDEPENDENT RISK-FACTOR; DIABETES-MELLITUS; PERIPHERAL NEUROPATHY; ATHEROSCLEROSIS RISK; LONG-TERM; INTERLEUKIN-6; TYPE-2; CANCER;
D O I
10.1186/s12885-020-06976-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among patients with smoldering MM (SMM). Methods Changes in various components of metabolic syndrome were investigated during the follow-up of patients with either MM or SMM compared to healthy controls. The data of 153 patients (105 with MM and 48 with SMM) and 138 controls were accessed from our medical center's records between 2008 and 2015. We analyzed the patients' data at diagnosis (baseline) and after 1, 3, and 5 years of follow-up. Results Patients with SMM had a significantly higher prevalence of diabetes, hypertension, and dyslipidemia at baseline compared to controls. A multivariate Cox regression analysis revealed a higher risk to develop dyslipidemia after 1, 3, and 5 years of follow-up among the SMM patients. The MM patients had a higher risk to develop diabetes after 1 year, hypertension after 5 years, and dyslipidemia after 1, 3, and 5 years of follow-up. Conclusions These data demonstrate that patients with SMM and those with MM are more prone to develop various components of metabolic syndrome, and they stress the importance of following-up metabolic syndrome components in both groups of patients.
引用
收藏
页数:8
相关论文
共 48 条
  • [1] The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma
    Alexandrakis, MG
    Passam, FH
    Ganotakis, ES
    Sfiridaki, K
    Xilouri, I
    Perisinakis, K
    Kyriakou, DS
    [J]. CLINICAL AND LABORATORY HAEMATOLOGY, 2003, 25 (01): : 41 - 46
  • [2] Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation
    Annaloro, C.
    Usardi, P.
    Airaghi, L.
    Giunta, V.
    Forti, S.
    Orsatti, A.
    Baldini, M.
    Delle Volpe, A.
    Deliliers, G. Lambertenghi
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 (09) : 797 - 804
  • [3] Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
    Badros, Ashraf
    Goloubeva, Olga
    Dalai, Jay S.
    Can, Llyas
    Thompson, Jennifer
    Rapoport, Aaron P.
    Heyman, Meyer
    Akpek, Gorgon
    Fenton, Robert G.
    [J]. CANCER, 2007, 110 (05) : 1042 - 1049
  • [4] Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension
    Bautista, LE
    Vera, LM
    Arenas, IA
    Gamarra, G
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2005, 19 (02) : 149 - 154
  • [5] Is C-reactive protein an independent risk factor for essential hypertension?
    Bautista, LE
    López-Jaramillo, P
    Vera, LM
    Casas, JP
    Otero, AP
    Guaracao, AI
    [J]. JOURNAL OF HYPERTENSION, 2001, 19 (05) : 857 - 861
  • [6] Promising therapies in multiple myeloma
    Bianchi, Giada
    Richardson, Paul G.
    Anderson, Kenneth C.
    [J]. BLOOD, 2015, 126 (03) : 300 - 310
  • [7] The insulin-like growth factor system in Multiple Myeloma: diagnostic and therapeutic potential
    Bieghs, Liesbeth
    Johnsen, Hans E.
    Maes, Ken
    Menu, Eline
    Van Valckenborgh, Els
    Overgaard, Michael T.
    Nyegaard, Mette
    Conover, Cheryl A.
    Vanderkerken, Karin
    De Bruyne, Elke
    [J]. ONCOTARGET, 2016, 7 (30) : 48732 - 48752
  • [8] Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults
    Calle, EE
    Rodriguez, C
    Walker-Thurmond, K
    Thun, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) : 1625 - 1638
  • [9] INTERLEUKIN-6 IS THE MAJOR REGULATOR OF ACUTE PHASE PROTEIN-SYNTHESIS IN ADULT HUMAN HEPATOCYTES
    CASTELL, JV
    GOMEZLECHON, MJ
    DAVID, M
    ANDUS, T
    GEIGER, T
    TRULLENQUE, R
    FABRA, R
    HEINRICH, PC
    [J]. FEBS LETTERS, 1989, 242 (02) : 237 - 239
  • [10] Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies
    Castillo, Jorge J.
    Mull, Nikhil
    Reagan, John L.
    Nemr, Saed
    Mitri, Joanna
    [J]. BLOOD, 2012, 119 (21) : 4845 - 4850